42 / 68
220
Ces Urol 2016; 20(3): 214–220
ORIGINÁLNÍ PRÁCE
11. Mita A, Denis L, Rowinski E, et al.
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A),
a novel taxane, administered as 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clin Cancer Res 2009; 15: 723.
12. Sweeney CJ, Chen YH, Carducci M, et al.
Chemohormonal therapy in metastatic hormon-senzitive
prostate cancer. N Eng J Med 2015; 373: 737–746.
13. Scher HI, Fizazi K, Saad F, et al.
Increased survival with enzalutamide in prostatae cancer after che‑
motherapy. N Engj J Med 2012; 367: 1187–1197.
14. de Bono JS, Logothesis CJ, Molina A, et al.
Abiraterone and increased survival in metastatic prostate
cancer. N Engl J Med 2011; 364: 1995–2005.
15. Caffo O, Pappagallo G, Brugnara S, et al.
Multiple rechallenges for castration-resistant prostate cancer
patients responding to first-line docetaxel: assesment of clinical outcomes and predictive factors. Urology
2012; 79: 644–649.
16. Oudard S, Kramer G, Caffo O, et al.
Docetaxel rechallenge after an initial good response in patients
with metastatic castration-resistant prostate cancer. BJU Int 2015; 115: 744–752.
17. Loriot Y, Massard C, Gross-Goupil M, et al.
The interval form the last cycle of docetaxel-based che‑
motherapy to progression is associated with efficacy of subsequent docetaxel in patients with prostatae
cancer. Eur J Cancer 2010; 46: 1770–1772.
18. Petrioli R, Francini E, Roviello G, et al.
Is there still a place for docetaxel rechallenge in prostate cancer?
World J clin Oncol 2015; 6: 99–103.
19. Ryan CJ, Smith MR, de Bono JS, et al.
Abirateron in metastatic prostatae cancer without previous
chemotherapy. N Engl J Med 2013; 368: 138–148.
20. Beer TM, Amstrong AJ, Rathkof DE, et al.
Enzalutamide in metastatic prostatae cancer before che‑
motherapy. N Engl J Med 2014; 371: 424–433.